Oseltamivir

C. diff Risk

None

Oral Bioavailability

Excellent

Spectrum Of Activity

Dosing

Treatment: 75mg PO BID x 5 days

Prophylaxis: 75mg PO daily until outbreak is over

10 - 30 eGFR31 - 60 eGFR60+ eGFR30mg PO every other day until outbreak is over30mg PO daily until outbreak is over75mg PO daily until outbreak is over

10 - 30 eGFR31 - 60 eGFR60+ eGFR30mg PO daily x 5 days30mg BID x 5 days75mg PO BID x 5 days

TREATMENT: 30mg po on DAY 1, then 30mg po after each HD for 5 days
PROPHYLAXIS: 30mg po on DAY 1, then 30mg po after each HD until outbreak is over

Treatment: 75mg PO daily x 5 days
Prophylaxis: 75mg PO every other day until outbreak is over

General Information

  • GI upset common

  • Rare - Stevens Johnson

  • Neuropsychiatric side effects reported

No significant

Will only treat Influenza A and B. Does NOT treat RSV, parainfluenza, human metapneumovirus, adenovirus, or other common viral pathogens
Higher doses have not been shown to be superior, but may be considered in critically ill or obese patients i.e. 150mg PO BID

Antimicrobial class: Antiviral - neuraminidase inhibitor

Pregnancy category: C

Average serum half life: 2.0

Lung penetration: Therapeutic

Treatment and prophylaxis of influenza A and B